These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38730427)

  • 1. DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy.
    Su PL; Chakravarthy K; Furuya N; Brownstein J; Yu J; Long M; Carbone D; Li Z; He K
    Mol Cancer; 2024 May; 23(1):97. PubMed ID: 38730427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer.
    Rudin CM; Reck M; Johnson ML; Blackhall F; Hann CL; Yang JC; Bailis JM; Bebb G; Goldrick A; Umejiego J; Paz-Ares L
    J Hematol Oncol; 2023 Jun; 16(1):66. PubMed ID: 37355629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DLL3: an emerging target in small cell lung cancer.
    Owen DH; Giffin MJ; Bailis JM; Smit MD; Carbone DP; He K
    J Hematol Oncol; 2019 Jun; 12(1):61. PubMed ID: 31215500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer.
    Isobe Y; Sato K; Nishinaga Y; Takahashi K; Taki S; Yasui H; Shimizu M; Endo R; Koike C; Kuramoto N; Yukawa H; Nakamura S; Fukui T; Kawaguchi K; Chen-Yoshikawa TF; Baba Y; Hasegawa Y
    EBioMedicine; 2020 Feb; 52():102632. PubMed ID: 31981983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.
    Morgensztern D; Besse B; Greillier L; Santana-Davila R; Ready N; Hann CL; Glisson BS; Farago AF; Dowlati A; Rudin CM; Le Moulec S; Lally S; Yalamanchili S; Wolf J; Govindan R; Carbone DP
    Clin Cancer Res; 2019 Dec; 25(23):6958-6966. PubMed ID: 31506387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges.
    Leonetti A; Facchinetti F; Minari R; Cortellini A; Rolfo CD; Giovannetti E; Tiseo M
    Cell Oncol (Dordr); 2019 Jun; 42(3):261-273. PubMed ID: 30968324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
    Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H;
    Oncologist; 2019 Nov; 24(11):e1172-e1179. PubMed ID: 31068386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth.
    Chen X; Amar N; Zhu Y; Wang C; Xia C; Yang X; Wu D; Feng M
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models.
    Lin S; Zhang Y; Yao J; Yang J; Qiu Y; Zhu Z; Hua H
    J Transl Med; 2024 Aug; 22(1):766. PubMed ID: 39143619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer.
    Tanaka K; Isse K; Fujihira T; Takenoyama M; Saunders L; Bheddah S; Nakanishi Y; Okamoto I
    Lung Cancer; 2018 Jan; 115():116-120. PubMed ID: 29290251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study.
    Blackhall F; Jao K; Greillier L; Cho BC; Penkov K; Reguart N; Majem M; Nackaerts K; Syrigos K; Hansen K; Schuette W; Cetnar J; Cappuzzo F; Okamoto I; Erman M; Langer SW; Kato T; Groen H; Sun Z; Luo Y; Tanwani P; Caffrey L; Komarnitsky P; Reinmuth N
    J Thorac Oncol; 2021 Sep; 16(9):1547-1558. PubMed ID: 33607312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
    Rudin CM; Pietanza MC; Bauer TM; Ready N; Morgensztern D; Glisson BS; Byers LA; Johnson ML; Burris HA; Robert F; Han TH; Bheddah S; Theiss N; Watson S; Mathur D; Vennapusa B; Zayed H; Lally S; Strickland DK; Govindan R; Dylla SJ; Peng SL; Spigel DR;
    Lancet Oncol; 2017 Jan; 18(1):42-51. PubMed ID: 27932068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FZ-AD005, a Novel DLL3-Targeted Antibody-Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models.
    Guo Q; Gao B; Song R; Li W; Zhu S; Xie Q; Lou S; Wang L; Shen J; Zhao T; Zhang Y; Wu J; Lu W; Yang T
    Mol Cancer Ther; 2024 Oct; 23(10):1367-1377. PubMed ID: 38940283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer.
    Mikami H; Feng S; Matsuda Y; Ishii S; Naoi S; Azuma Y; Nagano H; Asanuma K; Kayukawa Y; Tsunenari T; Kamikawaji S; Iwabuchi R; Shinozuka J; Yamazaki M; Kuroi H; Ho SSW; Gan SW; Chichili P; Pang CL; Yeo CY; Shimizu S; Hironiwa N; Kinoshita Y; Shimizu Y; Sakamoto A; Muraoka M; Takahashi N; Kawa T; Shiraiwa H; Mimoto F; Kashima K; Kamata-Sakurai M; Ishikawa S; Aburatani H; Kitazawa T; Igawa T
    Cancer Immunol Res; 2024 Jun; 12(6):719-730. PubMed ID: 38558120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TREM1/DAP12 based novel multiple chain CAR-T cells targeting DLL3 show robust anti-tumour efficacy for small cell lung cancer.
    Nie F; Chen Y; Hu Y; Huang P; Shi X; Cai J; Qiu M; Wang E; Lu K; Sun M
    Immunology; 2024 Jul; 172(3):362-374. PubMed ID: 38469682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the DLL3-targeting antibody-drug conjugate rovalpituzumab tesirine in preclinical models of neuroblastoma.
    Krytska K; Casey CE; Pogoriler J; Martinez D; Rathi KS; Farrel A; Berko ER; Tsang M; Sano RR; Kendsersky N; Erickson SW; Teicher BA; Isse K; Saunders L; Smith MA; Maris JM; Mossé YP
    Cancer Res Commun; 2022 Jul; 2(7):616-623. PubMed ID: 36381237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine.
    Van Den Borg R; Leonetti A; Tiseo M; Giovannetti E; Peters GJ
    Expert Rev Anticancer Ther; 2019 Jun; 19(6):461-471. PubMed ID: 31148500
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer.
    Udagawa H; Akamatsu H; Tanaka K; Takeda M; Kanda S; Kirita K; Teraoka S; Nakagawa K; Fujiwara Y; Yasuda I; Okubo S; Shintani M; Kosloski MP; Scripture C; Tamura T; Okamoto I
    Lung Cancer; 2019 Sep; 135():145-150. PubMed ID: 31446987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody-Drug Conjugate.
    Lashari BH; Vallatharasu Y; Kolandra L; Hamid M; Uprety D
    Drugs R D; 2018 Dec; 18(4):255-258. PubMed ID: 30232719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rovalpituzumab tesirine resistance: analysis of a corresponding small cell lung cancer and circulating tumor cell line pair.
    Rath B; Plangger A; Krenbek D; Hochmair M; Stickler S; Tretter V; Hamilton G
    Anticancer Drugs; 2022 Mar; 33(3):300-307. PubMed ID: 34924498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.